| scholarly article | Q13442814 |
| P50 | author | Andrew John Lees | Q4757729 |
| Henrik Zetterberg | Q6252048 | ||
| Christopher Morris | Q58340289 | ||
| Kaj Blennow | Q28321550 | ||
| Paola Giunti | Q30089859 | ||
| P2093 | author name string | K Bhatia | |
| N C Fox | |||
| R de Silva | |||
| C Mummery | |||
| J M Schott | |||
| N K Magdalinou | |||
| R W Paterson | |||
| T T Warner | |||
| P2860 | cites work | Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes | Q39713596 |
| α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study | Q39783457 | ||
| The glial marker YKL-40 is decreased in synucleinopathies | Q42441318 | ||
| Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus | Q42521348 | ||
| CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease | Q44422586 | ||
| Cerebrospinal fluid α-synuclein levels in Parkinson's disease--changed or unchanged? | Q45729318 | ||
| Identification of proteins secreted by human osteoblastic cells in culture | Q46128068 | ||
| A clinical rating scale for progressive supranuclear palsy | Q48219228 | ||
| Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies | Q48419671 | ||
| Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease | Q48438362 | ||
| Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? | Q48819771 | ||
| Corticobasal degeneration: clinical aspects | Q49076791 | ||
| Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. | Q50940972 | ||
| Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). | Q52888984 | ||
| Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups | Q59549757 | ||
| Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders | Q64763395 | ||
| What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study | Q64972096 | ||
| Alternate-form reliability of the Dementia Rating Scale-2 | Q81751534 | ||
| ??? | Q64781356 | ||
| Second consensus statement on the diagnosis of multiple system atrophy | Q24650965 | ||
| “Mini-mental state” | Q25938989 | ||
| Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 | ||
| The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations | Q28180426 | ||
| Parkinsonism: onset, progression, and mortality | Q28259134 | ||
| Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease | Q28275105 | ||
| Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases | Q29614910 | ||
| DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease | Q30493811 | ||
| Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression | Q30501271 | ||
| The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service | Q33183516 | ||
| YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor | Q33343967 | ||
| YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas | Q33719157 | ||
| Clinicopathological study of 35 cases of multiple system atrophy. | Q33733668 | ||
| Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions | Q34237637 | ||
| Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop | Q34733901 | ||
| The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal | Q36686188 | ||
| The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy | Q37536338 | ||
| Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management | Q38040822 | ||
| Does corticobasal degeneration exist? A clinicopathological re-evaluation | Q38415885 | ||
| Index for rating diagnostic tests | Q39605675 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| cerebrospinal fluid | Q54196 | ||
| biomarker | Q864574 | ||
| P304 | page(s) | 1240-1247 | |
| P577 | publication date | 2015-01-14 | |
| P1433 | published in | Journal of Neurology, Neurosurgery and Psychiatry | Q1599804 |
| P1476 | title | A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes | |
| P478 | volume | 86 |
| Q37648226 | A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology. |
| Q38653383 | A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations |
| Q38666247 | Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches |
| Q47754301 | Alpha-synuclein levels in patients with multiple system atrophy: a meta-analysis |
| Q39251035 | Applying fluid biomarkers to Alzheimer's disease |
| Q55307741 | Are We Ready for Detecting α-Synuclein Prone to Aggregation in Patients? The Case of "Protein-Misfolding Cyclic Amplification" and "Real-Time Quaking-Induced Conversion" as Diagnostic Tools. |
| Q64797205 | Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders |
| Q37676938 | Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder |
| Q64785496 | CSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD |
| Q64891208 | CSF Biomarkers of Neurodegeneration in Progressive Non-fluent Aphasia and Other Forms of Frontotemporal Dementia: Clues for Pathomechanisms? |
| Q93075108 | CSF and blood biomarkers for Parkinson's disease |
| Q50233550 | CSF neurogranin or tau distinguish typical and atypical Alzheimer disease |
| Q36071742 | Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort |
| Q47587631 | Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry |
| Q98210394 | Cerebrospinal fluid and blood levels of neurofilament light chain in Parkinson disease: A protocol for systematic review and meta-analysis |
| Q38825497 | Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice |
| Q58763366 | Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders |
| Q51298413 | Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis. |
| Q99566271 | Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson's disease |
| Q57493750 | Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease |
| Q89283722 | Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy |
| Q90591149 | Development of disease-modifying drugs for frontotemporal dementia spectrum disorders |
| Q64761571 | Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis |
| Q38915171 | Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases |
| Q36051094 | Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis |
| Q40053985 | Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: A systematic review and meta-analysis. |
| Q41163005 | Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia |
| Q42432396 | Differentiating atypical parkinsonian syndromes--a way forward? |
| Q39366291 | Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease. |
| Q37054024 | Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid |
| Q90107218 | Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease |
| Q26770708 | Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches |
| Q93108989 | Extracellular RNAs as Biomarkers of Sporadic Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases |
| Q38730062 | Impairment of mitochondria dynamics by human A53T α-synuclein and rescue by NAP (davunetide) in a cell model for Parkinson's disease. |
| Q36691986 | Increased CSF neurogranin concentration is specific to Alzheimer disease |
| Q96953378 | Increased Noradrenaline as an Additional Cerebrospinal Fluid Biomarker in PSP-Like Parkinsonism |
| Q36454535 | Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease |
| Q92735141 | Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms |
| Q37345484 | Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease |
| Q47708649 | Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders |
| Q54946040 | Molecular biomarkers of Alzheimer's disease: progress and prospects. |
| Q38813304 | Multiple system atrophy: pathogenic mechanisms and biomarkers |
| Q38392505 | Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update |
| Q57588817 | Neurofilaments as biomarkers in neurological disorders |
| Q92814294 | Neurofilaments: The C-Reactive Protein of Neurology |
| Q26749275 | Neurophysiological basis of rapid eye movement sleep behavior disorder: informing future drug development |
| Q89849041 | Phosphorylated Alpha-Synuclein in Red Blood Cells as a Potential Diagnostic Biomarker for Multiple System Atrophy: A Pilot Study |
| Q55110559 | Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes. |
| Q47663712 | Potential clinical utility of multiple system atrophy biomarkers |
| Q49892886 | Progressive Supranuclear Palsy: an Update |
| Q92339538 | Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes |
| Q58572579 | Recent Advances in Biomarkers for Parkinson's Disease |
| Q39010887 | Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting. |
| Q36708156 | Single-Molecule Imaging of Individual Amyloid Protein Aggregates in Human Biofluids |
| Q49920028 | Technological advances and changing indications for lumbar puncture in neurological disorders |
| Q52644601 | The Past and the Future of Alzheimer's Disease Fluid Biomarkers. |
| Q92465118 | The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis |
| Q31041660 | The role of biomarkers and imaging in Parkinson's disease. |
| Q38672062 | The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials |
| Q48887740 | Validation of soluble amyloid-β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases |
| Q92017939 | What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations? |
| Q91593341 | α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients |
Search more.